Table 5.

SGLT2 inhibitors that target hepatic lipid and glucose metabolism

Drug	Mechanism of action	Mode of administration	Regulatory status	Clinical effect					References
				Steatosis	Fibrosis markers	Hepatic enzymes	HbA1c	Insulin resistance
Empagliflozin	SGLT 2 inhibitor	PO	Phase IV	↓	↓=	↓	↓	↓Related to weight loss	[94, 95, 104, 175]
Canagliflozin	SGLT 2 inhibitor	PO	Phase IV	↓	NA	↓	↓	↓Related to weight loss	[97, 176–180]
Dapagliflozin	SGLT 2 inhibitor	PO	Phase IV	↓	NA	↓	↓	↓Related to weight loss	[70, 96, 181–183]
Ertugliflozin	SGLT 2 inhibitor	PO	Phase IV	NA	NA	↓	↓	↓Related to weight loss	[184]
Ipragliflozin	SGLT 2 inhibitor	PO	Approved by PMDA	↓	↓Tendency	↓	↓	↓Related to weight loss	[62, 101, 185–190]
Tofogliflozin	SGLT 2 inhibitor	PO	Approved by PMDA	↓	NA	↓	↓	↓Related to weight loss	[191]
Luseogliflozin	SGLT 2 inhibitor	PO	Approved by PMDA	↓	NA	↓	↓	↓Related to weight loss	[99, 100]
Licogliflozin (LIK066)	Dual SGLT1/2 inhibitor	PO	Phase IIa	↓	NA	↓	↓	↓Related to weight loss	[192, 193]

PO, oral; PMDA, Pharmaceuticals and Medical Devices Agency, Japan